Study start date: September 1, 1989Actual date on which the first participant was enrolled.
The purpose of this study is to assess the safety and effectiveness of buprenorphine for treatment of concurrent intravenous heroin and cocaine dependence.
Official TitleTreatment Efficacy for Drug Abuse and AIDS Prevention
Principal SponsorNational Institute on Drug Abuse (NIDA)
This section provides details of the study plan, including how the study is designed and what the study is measuring.
Design Details
0
Treatment Study
These studies test new ways to treat a disease, condition, or health issue. The goal is to see if a new drug, therapy, or approach works better or has fewer side effects than existing options.
Eligibility
Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.
Conditions
Criteria
MaleBiological sex of participants that are eligible to enroll.
From 26 to 41 YearsRange of ages for which participants are eligible to join.
Healthy volunteers not allowedIf individuals who are healthy and do not have the condition being studied can participate.
Conditions
Pathology
Cocaine-Related Disorders
Heroin Dependence
Criteria
No eligibility criteria are available at this time.Please check with the study contact for more details.
Ensure optimum compatibilityAdd your profile to know your probability eligibility score.
Study Centers
These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.
This study has 1 location
Suspended
McLean Hospital, Dept. of PsychiatryBelmont, United StatesSee the location
CompletedOne Study Center
English
Treatment Efficacy for Drug Abuse and AIDS Prevention - 2 | PatLynk